Fluconazole resistant Candida auris clinical isolates have increased levels of cell wall chitin and increased susceptibility to a glucosamine-6-phosphate synthase inhibitor

In 2009 Candida auris was first isolated as fungal pathogen of human disease from ear canal of a patient in Japan. In less than a decade, this pathogen has rapidly spread around the world and has now become a major health challenge that is of particular concern because many strains are resistant to multiple class of antifungal drugs. The lack of available antifungals and rapid increase of this fungal pathogen provides an incentive for the development of new and more potent anticandidal drugs and drug combinatorial treatments. Here we have explored the growth inhibitory activity against C. auris of a synthetic dipeptide glutamine analogue, L-norvalyl-N 3-(4-methoxyfumaroyl)-L-2,3- diaminopropanoic acid (Nva-FMDP), that acts as an inhibitor of glucosamine-6-phosphate (GlcN-6-P) synthase - a key enzyme in the synthesis of cell wall chitin. We observed that in contrast to FLC susceptible isolates of C. auris, FLC resistant isolates had elevated cell wall chitin and were susceptible to inhibition by Nva-FMDP. The growth kinetics of C. auris in RPMI-1640 medium revealed that the growth of FLC resistant isolates were 50-60% more inhibited by Nva-FMDP (8 μ g/ml) compared to a FLC susceptible isolate. Fluconazole resistant strains displayed increased transcription of CHS1, CHS2 and CHS3, and the chitin content of the fluconazole resistant strains was reduced following the Nva-FMDP treatment. Therefore, the higher chitin content in FLC resistant C. auris isolates may make the strain more susceptible to inhibition of the antifungal activity of the Nva-FMDP peptide conjugate.

Mimosine facilitates metallic cation uptake by plants through formation of mimosine-cation complexes

Iron deficiency conditions as well as iron supplied as a Fe(III)-mimosine complex induced a number of strategy I and strategy II genes for iron uptake in leucaena. Leucaena leucocephala (leucaena) is a tree-legume that can grow in alkaline soils, where metal-cofactors like Fe(III) are sparingly available. Mimosine, a known chelator of Fe(III), may facilitate Fe(III) uptake in leucaena by serving as a phytosiderophore. To test if mimosine can serve as a phytosiderophore, three sets of experiments were carried out. First, the binding properties and solubility of metal-mimosine complexes were assessed through spectrophotometry. Second, to study mimosine uptake in plants, pole bean, common bean, and tomato plants were supplied with mimosine alone and metal-mimosine complexes. Third, the expression of strategy I (S1) and strategy II (S2) genes for iron uptake from the soil was studied in leucaena plants exposed to different Fe(III) complexes. The results of this study show that (i) mimosine has high binding affinity for metallic cations at alkaline pH, Fe(III)-mimosine complexes are water soluble at alkaline pH, and that mimosine can bind soil iron under alkaline pH; (ii) pole bean, common bean, and tomato plants can uptake mimosine and transport it throughout the plant; and (iii) a number of S1 and S2 genes were upregulated in leucaena under iron-deficiency condition or when Fe(III) was supplied as a Fe(III)-mimosine complex. These findings suggest that leucaena may utilize both S1 and S2 strategies for iron uptake; and mimosine may play an important role in both strategies.

Prodrug approach to improve absorption of prednisolone

Amino acid and dipeptide prodrugs have been developed to examine their potential in enhancing aqueous solubility and permeability as well as to bypass P-glycoprotein (P-gp) mediated cellular efflux of prednisolone. Prodrugs have been synthesized and identified with LC/MS/MS and NMR. Prodrugs displayed significantly higher aqueous solubility relative to prednisolone. These compounds also exhibited higher stability under acidic conditions relative to basic medium. [14]-Erythromycin uptake remained unaltered in the presence of valine-valine-prednisolone (VVP) indicating lower affinity toward P-gp. Moreover, VVP generated significantly higher transepithelial permeability across MDCK-MDR1 cells compared to prednisolone. Importantly, [3H]-GlySar uptake diminished significantly in the presence of VVP indicating high affinity toward peptide transporters. Moreover, prednisolone was regenerated from VVP due to enzymatic hydrolysis in SIRC cell homogenate. Results obtained from these studies clearly suggest that peptide transporter targeted prodrugs is a viable strategy to improve aqueous solubility and overcome P-gp mediated cellular efflux of prednisolone.

Effect of a new opioid peptide on opioid receptor and peptide transporter gene of brain and small intestinal tissues in mice

AIM: To investigate the effect of a new opioid peptide, YPFPGPIRYG, on the opioid receptor and peptide transporter gene of brain and small intestinal tissues via gastrointestinal tracts at transcription level.

METHODS: Twenty-four mice were randomly divided into opioid group (n = 12) and control group (n = 12), which were fed with 8×10^-7 mol/L YPFPGPIRYG and double distilled water, respectively, for 2 wk. The total RNA was extracted from the brain and small intestinal tissues of mice for the detection of μ-, δ-opioid receptor and peptide transporters PepT1 gene expression by reverse transcription-polymerase chain reaction (RT-PCR).

RESULTS: In the brain and small intestinal tissues, μ- and δ-opioid receptor transcripts were detected, while peptide transporter PepT1 was only found to be expressed in the small intestine. In comparison with those in the controls, the expression of μ- and δ-opioid receptor were significantly enhanced in the small intestine (P < 0.05), but not in the brain, and PepT1 gene expression was not changed in the intestinal tissues of mice treated with YPFPGPIRYG.

CONCLUSION: Opioid receptor expression has tissue specificity. The immunomodulatory effects of opioid YPFPGPIRYG do not attribute to the interaction with the opioid receptors in central nervous system (CNS), but with d- and m-opioid receptor in small intestine.